OR WAIT 15 SECS
© 2020 MJH Life Sciences and BioPharm International. All rights reserved.
© 2020 MJH Life Sciences™ and BioPharm International. All rights reserved.
October 16, 2020
Bio/Pharma companies are galvanized to develop COVID-19 therapies under FDA’s acceleration program.
October 01, 2020
The acquisition will support the accelerated commercialization of Kyslecel (autologous pancreatic islets), Koligo’s personalized cell therapy for treating pancreatitis.
September 18, 2020
The collaboration will expand the manufacturing capacity for lenzilumab, a COVID-19 therapeutic candidate, in advance of a potential Emergency Use Authorization in 2020.
The agreement will Increase global manufacturing capacity for Novavax’s vaccine candidate, NVX-CoV2373, to more than two-billion annualized doses when at full capacity in 2021.
The agreement between the two companies will significantly increase global supply capacity for Lilly's potential COVID-19 treatments.
September 02, 2020
The companies have entered into a strategic partnership for the CMC development and manufacturing of Ansun’s biologics pipeline.
The companies provided an update stating that the biologic did not meet a primary endpoint in a Phase III clinical trial when compared with placebo in the treatment of COVID-19 patients.
The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.
September 01, 2020
Current and newer biologic modalities pose increasingly complex challenges to the detection and characterization of protein aggregates.
August 28, 2020
The company has appointed Liam Tayler as CEO to guide the growth of the company’s iPSC technologies, products, and services.